Sarepta Therapeutics, Inc. (SRPT)
NASDAQ: SRPT · Real-Time Price · USD
15.68
-0.20 (-1.26%)
At close: Jul 24, 2026, 4:00 PM EDT
15.88
+0.20 (1.28%)
Pre-market: Jul 27, 2026, 4:01 AM EDT
Sarepta Therapeutics Stock Forecast
Stock Price Forecast
According to 23 analysts polled by S&P Global, Sarepta Therapeutics stock has a consensus rating of "Hold" and an average price target of $22.17. The average 1-year stock price forecast is 41.39% higher than the current stock price, while the lowest is $5.00 (-68.11%) and the highest is $38 (+142.35%).
Price Target: $22.17 (+41.39%)
Analyst Consensus: Hold
Price Target
ChartAnalyst Ratings
The average analyst rating for Sarepta Therapeutics stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 8 | 6 | 6 | 7 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 13 | 13 | 12 | 13 | 13 | 11 |
| Sell | 2 | 2 | 2 | 2 | 2 | 2 |
| Strong Sell | 3 | 3 | 3 | 3 | 3 | 3 |
| Total | 25 | 25 | 25 | 24 | 24 | 23 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citi | Citi | Sell Maintains $13 | Sell | Maintains | $13 | -17.09% | Jul 21, 2026 |
| Bank of America Securities | Bank of America Securities | Sell Reiterates $19 | Sell | Reiterates | $19 | +21.17% | Jul 15, 2026 |
| Mizuho Securities | Mizuho Securities | Buy Maintains $31 | Buy | Maintains | $31 | +97.70% | Jul 10, 2026 |
| Piper Sandler | Piper Sandler | Hold Reiterates $20 | Hold | Reiterates | $20 | +27.55% | Jul 9, 2026 |
| Wolfe Research | Wolfe Research | Buy Upgrades $27 | Buy | Upgrades | $27 | +72.19% | Jul 8, 2026 |
Financial Forecast
Revenue This Year
1.84B
from 2.20B
Decreased by -16.31%
Revenue Next Year
1.41B
from 1.84B
Decreased by -23.44%
EPS This Year
4.79
from -5.05
EPS Next Year
2.45
from 4.79
Decreased by -48.85%
EPS and Forward PE are based on non-GAAP adjusted numbers.